Vitamin E Supplementation and Plasma 8-Isoprostane and Adiponectin in Overweight Subjects
Article first published online: 6 SEP 2012
2007 North American Association for the Study of Obesity (NAASO)
Volume 15, Issue 2, pages 386–391, February 2007
How to Cite
Sutherland, W. H. F., Manning, P. J., Walker, R. J., De Jong, S. A., Ryalls, A. R. and Berry, E. A. (2007), Vitamin E Supplementation and Plasma 8-Isoprostane and Adiponectin in Overweight Subjects. Obesity, 15: 386–391. doi: 10.1038/oby.2007.546
- Issue published online: 6 SEP 2012
- Article first published online: 6 SEP 2012
- Received for review March 01, 2006, Accepted in final from September 22, 2006
- oxidative stress;
- vitamin E
Objective: Isoprostanes are a marker of oxidant stress and atherosclerotic risk, and plasma concentrations are elevated in obesity. Adiponectin is a regulator of insulin sensitivity, and low circulating levels are associated with oxidant stress and obesity. The aim of this study was to determine the effect of vitamin E supplementation on plasma concentrations of 8-isoprostane and adiponectin in overweight/obese subjects.
Research Methods and Procedures: The study was a 6-month, randomized, double-blind, placebo-controlled trial in 80 overweight subjects (60 women and 20 men, BMI >27 kg/m2). Exclusion criteria were serious illness, smoking, or taking antioxidant supplements. Participants were randomized to receive 800 IU/d natural vitamin E (n = 39) or placebo (n = 41) for 3 months with an increase in the dose to 1200 IU/d for a further 3 months. Plasma 8-isoprostane and adiponectin concentrations were measured at baseline and 3 and 6 months.
Results: During 6 months of supplementation with vitamin E, plasma vitamin E concentration increased significantly (p < 0.001) by 76%, and plasma 8-isoprostane concentrations decreased significantly (−11%, p = 0.03), whereas plasma adiponectin concentrations did not change significantly.
Discussion: These findings suggest that supplementation with high-dose vitamin E decreases systemic oxidative stress and 8-isoprostane concentrations in overweight/obese individuals. A decrease in plasma 8-isoprostane has the potential to reduce risk of cardiovascular disease in obesity.